Clinical trials: Manic Depression
Depression
Study Comparing Outcomes for Patients With Treatment Resistant Depression Who Receive VNS Therapy at Different Doses
This is a postmarket medical device study. The objective of this study is to compare the safety and effectiveness of Vagus Nerve Stimulation (VNS) Therapy administered at different amounts of electrical charge for the treatment…
- Trial name
- NCT00305565
- Testing
- VNS Therapy
- Where
- 26 sites in United States
- Volunteers
- 331 people
- Sponsor
- Cyberonics, Inc.
Bipolar Disorder
A Double-Blind Placebo Controlled Trial of Riluzole in Bipolar Depression
The Johns Hopkins Department of Psychiatry is conducting a research study to examine the effectiveness of riluzole in treating the depressed phase of bipolar disorder.
- Trial name
- NCT00376220
- Testing
- Riluzole
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- Johns Hopkins University
Schizophrenia, Bipolar Disorder
Early Detection and Intervention for the Prevention of Psychosis
EDIPP is a multisite trial of early identification and intervention to prevent the onset of psychosis in adolescents and young adults, carried out at six sites across the United States.
- Conditions
- Schizophrenia, Bipolar Disorder, Depression, Psychotic Disorders
- Trial name
- EDIPP (NCT00531518)
- Testing
- aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine, Psychoeducational multifamily group treatment, Supported employment and education
- Where
- 6 sites in United States
- Volunteers
- 292 people
- Sponsor
- MaineHealth
Bipolar Disorder
Cost- Effectiveness and Quality of Life Assessment in Bipolar Disorder Depressive Episode
To evaluate the effectiveness of an algorithm for Bipolar Disorder depressive episodes (BDD) using medications available in the Brazilian Public Healthcare System (SUS).
- Trial name
- NCT02918097
- Testing
- Lithium Carbonate, Sertraline, Nortriptyline
- Volunteers
- 78 people
- Sponsor
- Federal University of Rio Grande do Sul
Bipolar Disorder, Alcoholism
Aripiprazole for Bipolar Disorder and Alcohol Use Disorder
The investigators will conduct a 12-week, randomized, double-blind, parallel-group, placebo-controlled study of aripiprazole in 132 persons with Alcohol Use Disorder (AUD) and bipolar I or II disorder, currently depressed or…
- Conditions
- Bipolar Disorder, Alcoholism, Alcohol Abuse
- Trial name
- NCT02918370
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Texas Southwestern Medical Center
Bipolar Depression
Brexpiprazole for Bipolar Depression
The investigators will conduct an 8-week, non-randomized, open-label study of brexpiprazole in 20 persons with bipolar I or II disorder, depressed mood state.
- Trial name
- NCT03427892
- Testing
- Brexpiprazole
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Texas Southwestern Medical Center
Bipolar Disorder
Nutrition, Exercise, and Wellness Treatment (NEW Tx) for Bipolar Disorder
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in bipolar disorder, yet no empirically validated psychosocial interventions to manage risk factors for CVD in BD have been developed.
- Trial name
- NEW Tx (NCT01615367)
- Testing
- Nutrition, Exercise, and Wellness (NEW) psychotherapy, Typically consists of at least one FDA-approved mood stabilizer
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Massachusetts General Hospital
Bipolar Disorder, Psychosis
Treatment to Enhance Cognition in Bipolar Disorder
The purpose of the present study is to evaluate a neuroplasticity-oriented, computer-based cognitive remediation treatment program in patients with bipolar disorder and its effects on cognitive deficits and community functioning…
- Trial name
- TREC-BD (NCT01470781)
- Testing
- BrainWorks, Computer Control
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Mclean Hospital
Bipolar Disorder
Genetic Predictors of Lithium Response in Bipolar Disorder
The purpose of this study is to identify genetic predictors of lithium response in bipolar disorder.
- Trial name
- NCT00252577
- Testing
- Lithium treatment
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- VA Office of Research and Development
Treatment- Resistant Bipolar Disorder, Bipolar Disorder
Nitrous TRD Bipolar Depression
Investigators will study approximately 64 patients with Treatment-Resistant Bipolar Depressive Disorder, defined as a failure of at least 1 antidepressants in the current depressive episode and 2 lifetime medication failures.
- Conditions
- Treatment- Resistant Bipolar Disorder, Bipolar Disorder, Bipolar Depressive Disorder
- Trial name
- NCT02757521
- Testing
- Nitrous Oxide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Washington University School of Medicine
Major Depressive Disorder, Bipolar Disorder
The Role of Dopamine Metabolism in the Antidepressant Effects of Sleep Deprivation and Sertraline in Depressed Patients
This study evaluates the efficacy of sleep deprivation treatment in accelerating antidepressant responses when administered during the first week of medications and augmenting a sustained response with chronobiological…
- Trial name
- NCT00581009
- Testing
- chronobiological augmentation, sertraline, lithium, one night of sleep deprivation and two FDG PET scans
- Where
- 2 sites in United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- University of California, Irvine
Bipolar Disorder, Bipolar I Disorder
Evaluating the Hypothesized Mechanism of Action of N-acetylcysteine for Bipolar Disorder
This research study evaluates the effects of anFDA-approved medication NAC in individuals with Bipolar Disorder. Participants in the study will will be assigned to two medication conditions and will take both NAC and a matched…
- Conditions
- Bipolar Disorder, Bipolar I Disorder, Bipolar II Disorder
- Trial name
- NCT05340504
- Testing
- N-Acetyl cysteine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Medical University of South Carolina
Bipolar Disorder
Cost- Effectiveness and Quality of Life Assessment in Mood Disorder
To evaluate the effectiveness of three systematic interventions for Bipolar Disorder (BD) mixed episodes using medications available in the Brazilian Public Healthcare System (SUS), and assessment of the quality of life of these…
- Trial name
- NCT02870283
- Testing
- Lithium, Valproic Acid, Carbamazepine
- Volunteers
- 107 people
- Sponsor
- Federal University of Rio Grande do Sul
Schizophrenia, Bipolar Disorder
Individualizing Incentives for Alcohol in the Severely Mentally Ill
The investigators will evaluate the efficacy of a 2 various contingency management (CM) interventions (High-Magnitude CM, Shaping CM) for treating heavy drinking among individuals with serious mental illness and alcohol…
- Conditions
- Schizophrenia, Bipolar Disorder, Major Depressive Disorder, Alcohol Dependence
- Trial name
- NCT03481049
- Testing
- Usual CM, High-Magnitude CM, Shaping CM
- Where
- 2 sites in United States
- Volunteers
- 392 people, healthy volunteers welcome
- Sponsor
- Washington State University
Schizophrenia, Schizoaffective Disorder
Improving Diabetes Risk Factors in Persons With Schizophrenia or Bipolar Disorder by Switching to Ziprasidone
Having a diagnosis of schizophrenia or bipolar disorder and being treated with certain of the newer antipsychotics are risk factors for development of diabetes.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT00538642
- Testing
- ziprasidone
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Bipolar Disorder, Bipolar Depression
PET and MRI Brain Imaging of Bipolar Disorder
The primary aims of this study are to: 1. Quantify serotonin transporter (5-HTT) binding potential (BP) in vivo in bipolar disorder patients (BPD) during a major depressive episode (MDE). 2.
- Conditions
- Bipolar Disorder, Bipolar Depression, Unipolar Depression
- Trial name
- NCT01880957
- Testing
- Lithium, Lamotrigine
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Stony Brook University
Psychosis, Substance Use
Families With Substance Use and Psychosis: A Pilot Study
The purpose of this study is to develop and evaluate an intervention that adapts Community Reinforcement and Family Training (CRAFT) for families experiencing first episode psychosis and substance use delivered via telemedicine…
- Conditions
- Psychosis, Substance Use, Substance Use Disorders, Family
- Trial name
- NCT04284813
- Testing
- CRAFT-FT
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Mclean Hospital
Bipolar Disorder, Cocaine Dependence
Citicoline for Bipolar 1 Disorder and Cocaine Dependence
A 12-week, randomized, double-blind, parallel-group, placebo-controlled trial of citicoline as an add-on therapy will be conducted in 200 outpatients with bipolar I disorder and cocaine dependence.
- Trial name
- NCT00619723
- Testing
- Citicoline, Cognitive Behavioral Therapy (CBT)
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Bipolar Disorder
Effect of Oxcarbazepine on Serum Brain Derived Neurotrophic Factor (BDNF) in Bipolar Disorder
The present study has been designed to evaluate the change in serum BDNF level with oxcarbazepine monotherapy in bipolar disorder and to explore the possibility of its neuroprotective effect.
- Trial name
- NCT02456896
- Testing
- Oxcarbazepine
- Where
- India
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Bipolar Disorder Mania
Study to Evaluate the Efficacy and Safety of Aripiprazole Administered With Lithium or Valproate Over 12 Weeks in the Treatment of Mania in Bipolar I Disorder
The purpose of the study is to determine whether aripiprazole provides additional clinical benefit to patients with Bipolar I disorder when combined with lithium or valproate over 12 weeks.
- Trial name
- NCT00665366
- Testing
- Aripiprazole, Lithium, Valproate
- Where
- 73 sites in Austria, Czechia and 11 more
- Volunteers
- 493 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.